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More than two billion people in low- and middle-income 
countries (LMIC) lack adequate access to essential medicines [1]. 
The problem is complex and views of stakeholder responsibilities 
to solve it differ.
Increasingly, demands are being placed on the pharmaceutical 
industry to contribute to improving access to medicines for poor 
patients in developing countries [2,3]. A consensus on what 
constitutes an appropriate portfolio of corporate responsibilities 
for access to medicines – under conditions of failing states and 
market failure – is in the interest of the world’s poor and of 
corporations that want to be part of the solution for one of the 
most pressing social issues of our time.
In this paper, we provide public health, human rights and 
economic arguments for improving access to medicines 
and discuss the different roles and responsibilities of key 
stakeholders. We then establish a framework of pharmaceutical 
firms’ corporate responsibilities and make recommendations 
for actionable business strategies for improving access to 
medicines. We aim to contribute to constructive dialogue on the 
responsibilities of the pharmaceutical industry and its activities 
of good corporate practice. We conclude that partnerships and 
collaboration among multiple stakeholders are urgently needed 
to improve equitable access to medicines in LMICs.
Improving Access to Medicines – 
Health, Human Rights and Economic 
Rationales 
WHO’s Director General, Dr. Margaret Chan, asserts that, “much 
of the ill health, disease, premature death and suffering we see 
on such a large scale is needless, as effective and affordable 
interventions are available for prevention and treatment [4].” 
Essential medicines are such interventions. Used properly, 
essential medicines and vaccines could save up to 10.5 million 
lives each year and reduce unnecessary suffering [5].
However, a third of the world’s population (up to 50 percent in 
parts of Asia and Africa) lack access to essential medicines [6].
Average availability of generic medicines is only 38 percent in 
the public sector in LMIC [7]. Although private sector availability 
is higher – on average 64 percent – medicines in private 
pharmacies are often not affordable [7]. Consuming 25-65 
percent of total public and private spending on health and 60-
90 percent of household expenditure on health in developing 
countries, [8] medicines pose an enormous economic burden 
on health systems and households. Unfortunately, spending on 
medicines is often not cost-effective: almost half of all medicines 
are inappropriately prescribed, dispensed, or sold and patients 
do not adhere to about 50 percent of the medicines they receive 
[5,9].
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Published Online: 27th Dec 2012There is a strong human rights argument for improving access 
to medicines [10]. Given that morbidity and mortality can 
be reduced by ‘good governance’ and spending resources 
according to actual needs, [11] and that medicines are vital for 
good health, there is a moral imperative for evidence-based 
policies and fair distribution of resources to improve access to 
medicines for the poor and vulnerable.  
Similarly, there is a strong economic argument for improving 
access to medicines in LMICs. Today, about 2.5 billion people 
struggle to meet their basic needs [12]. In a vicious circle of 
poverty and illness, poverty is a both cause and an effect of poor 
health [13] and lack of access to medicines. Since health of their 
bodies and minds is often the only asset of poor people, access 
to medicines becomes particularly crucial for them. 
Experts concur on the dismal state of access to medicines in 
LMICs. There is less agreement on sources of the problem, and 
while there are strong public health, human rights and economic 
arguments for improving access to medicines in LMIC, there is 
little consensus on who is responsible for action.
Improving Access to Medicines – 
Responsibilities of Stakeholders
Primary Duty Bearer
The Nation State, supported by the international community, 
bears the primary responsibility for ensuring that the right to 
health is respected, protected, and fulfilled [10].
WHO holds the “failure of health systems” [4] responsible for 
the “unacceptably low” health outcomes across much of the 
developing world. If low-income countries devoted 15 percent 
of their national budgets to health and added appropriate 
development assistance, they could finance adequate primary 
health care for the poor [14]. However, governments of many 
developing countries continue to spend most resources on 
sectors other than health and education [15,16] and scarce 
resources on health are wasted or misallocated, [17] often as 
a result of politics or corruption. Nevertheless, governments 
can facilitate significant progress toward improving access 
to medicines, even under budget constraints. For example, 
governments can abolish import tariffs, duties, and sales taxes 
on medicines, which contribute little to government budgets, 
unfairly tax the poor, and increase end-user prices of medicines 
in the public sector, sometimes by more than 80 percent [7,18].
Where capacity and efficacy in the public sector are still low, 
adopting strategies that place a greater workload on public 
institutions may prove detrimental [19]. Other actors must 
therefore assist to facilitate improvements.The international 
community, nongovernmental organizations (NGOs) and the 
pharmaceutical industry share responsibilities for improving 
access to medicines. However, their contributions will only be as 
effective as national political and social constraints will allow [4].
Other Duty Bearers 
International Community
International recommendations [11] and binding treaties [20] 
outline the roles of the international community in development 
assistance. In the Millennium Declaration, 147 heads of state 
and governments “recognize that, in addition to our separate 
responsibilities to our individual societies, we have a collective 
responsibility to uphold the principles of human dignity, equality 
and equity at the global level [21].”
Despite global commitment and unprecedented amounts of 
donor support, international efforts to improve medicines 
access leave much room for improvement. Programs that rely 
on donor funding are at risk when donor countries – themselves 
under financial pressure - fail to honor their commitments 
[22]. For decades, the international community has neglected 
programs for treatment of non-communicable diseases [23].
International development assistance, which is often targeted 
at specific diseases rather than general health sector support 
[24], may actually hinder progress towards broader public health 
goals [25].
With respect to medicines access, international community 
efforts might benefit from coordination, a focus on strengthening 
health systems across vertical programs, and evaluation of the 
desired and undesired impacts of interventions [25].
Non-Governmental Organizations
Many NGOs play a vital role in development and in almost 
all aspects of health-related work for the poor. In contrast to 
governments (and pharmaceutical companies), NGOs tend to 
score highly among poor people on responsiveness and trust 
[26]. NGOs raise public awareness for health care issues affecting 
the poor, support policies that directly benefit the poor, supply 
medicines, and deliver care. NGOs have also been integral to 
promoting a rights-based approach to pharmaceutical policy 
[10] and pressing for more comprehensive corporate awareness 
of, and responsibility for, access to medicines [2].
However, like the international community, NGOs often focus 
on specific diseases, notably HIV/AIDS and little attention has 
been paid to access to medicines for other high-impact diseases 
and health system improvement [24].
In recognition of NGOs’ value, the Millennium Declaration 
recommends that greater opportunities be given to NGOs to 
contribute towards global health goals [21]. NGOs can play a 
critical role in campaigning for increased and better-coordinated 
resources for health care and promoting sustainable health 
systems, notably for chronic disease treatment. NGOs 
should continue to monitor, and hold accountable, country 
governments and pharmaceutical companies with respect to 
their responsibilities and commitments to improving access to 
medicines [10].
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Pharmaceutical Industry
Finally, pharmaceutical companies, as the developers and 
manufacturers of medicines, play a key role in improving access 
to medicines. Millennium Development Goal 8 sets out the 
target for the international community “in co-operation with 
pharmaceutical companies, [to] provide access to affordable, 
essential drugs in developing countries [27]. ”The corporate 
right-to-health obligation is laid out in the preamble to the 
Universal Declaration of Human Rights: “every individual and 
every organ of society… shall strive… to promote respect for 
these rights and freedoms and… to secure their universal and 
effective recognition and observance” [emphasis added] [28].
There is extensive debate on what the human rights focus should 
mean for pharmaceutical corporations, as organs of society.
While some criticize today’s pharmaceutical business model for 
ensuring “maximum margins” by charging what the market can 
bear and by “defending patents unreservedly,” [2] investors and 
financial analysts who assess pharmaceutical companies expect 
nothing less [29].
The common good is best served when all actors in all 
social subsystems do their best in the area of their particular 
responsibility, without losing sight of the ties that bind them 
[30]. What is then the “particular responsibility” of the 
pharmaceutical industry, and how can corporations fulfill their 
social contract? 
Responsibilities of the Pharmaceutical 
Industry – Evolving Paradigms
The role of a pharmaceutical company in a global economy 
is to research, develop and produce innovative medicines 
that improve quality of life, and it is their duty to do so 
in a profitable way. No other societal actor assumes this 
responsibility. A company can only realize sustained earnings 
if and when it uses its resources in a socially responsible, 
environmentally sustainable, and politically acceptable way. 
Given an increasing investor and consumer focus on corporate 
social responsibility, it is in the enlightened self-interest of a 
pharmaceutical company to be part of the solution to the 
access to medicines problem. Encouragingly, more companies 
participate in the bi-annual Access to Medicines Index which 
provides “pharmaceutical companies, investors, governments, 
academics, nongovernmental organizations and the general 
public with independent, impartial and reliable information on 
individual pharmaceutical companies’ efforts to improve global 
access to medicine [31].”
Responsibilities of the Pharmaceutical 
Industry – Controversies around 
Profits and Patents
Although critics argue for the weakening of intellectual 
property rights, patents should not be the focus of the access 
to medicines debate. Patents provide desirable incentives and 
are a precondition for successful research and development 
of innovative drugs and vaccines. Access to pharmaceutical 
innovations for poor patients requires an intelligent mix of 
public and private research and incentives. The challenge is 
to find innovative strategies for the responsible use of patents 
under conditions of market failure. Creative ideas are emerging 
[32], for example, for the development of new antibiotics [33] 
and medicines for neglected diseases [34].
Patents are not the reason for lack of access to essential 
medicines that are already developed. In 65 LMICs where four 
billion people live, patenting is rare for products on WHO’s 
Model List of Essential Medicines: only 17 of the 319 products 
were patentable, and only in 1.4% of instances (300 out of 
20,735 essential medicine-country combinations) were essential 
medicines patented, mostly in larger markets [35]. However, 
lack of patents does not guarantee that generic medicines are 
available [7] or acceptable [36] in LMICs, confirming that all 
stakeholders must do their parts to improve availability, quality, 
perception, and use of generic products.  
Responsibilities of the Pharmaceutical 
Industry – A Framework
There are three levels of corporate responsibility: the “must,” 
the “ought to,” and the “can” dimensions [Figure 1] [37].
Pharmaceutical firms “must” develop new medicines, make 
a profit, and comply with applicable laws and regulations. 
Voluntary corporate activities to improve access to medicines 
can be classified as either corporate responsibility (“ought 
to”) or philanthropy (“can”). Exactly which activities fall into 
each category may be debated, and given evolving paradigms, 
companies may increasingly consider access to medicines 
activities beyond legal duties consistent with business strategy.
Figure 1. The Hierarchy of Corporate Responsibilityi
i Modified from figure previously published in Leisinger (2009).37
Improving Access to Medicines in Low and Middle Income Countries
Southern Med Review Vol 5 Issue 2 December 20126
Research-based pharmaceutical companies have committed 
to improving access to medicines [38,39]. Figure 2 includes 
corporate activities recommended by the International Federation 
of Pharmaceutical Manufacturers Association (IFPMA), [38] the 
UK Department for International Development (DFID) [40] and 
the United Nations [41] to improve access to essential medicines 
in LMIC and develop medicines for neglected diseases. While all 
of these corporate activities could be viewed as philanthropic 
(“can”) endeavors, many should also be considered as a part 
of a firms’ corporate responsibility (“ought to”) and business 
model. 
Figure 2:  Promising Corporate Responsibility Tools to Improve 
Access to Medicines
    Differential pricing: adapt prices for selected, particularly 
patent-protected, medicines to the purchasing power of 
consumers in different countries and socio-economic groups 
(also known as tiered pricing).
    Donations: donate medicines for disease eradication programs 
or emergencies, adhering to WHO Guidelines for Drug 
Donations.
    Health system strengthening: provide support for broader 
health and development goals in developing countries.
    Patent pools: participate in voluntarily mechanisms to make 
intellectual property available to entities, including generic 
manufacturers, which develop and manufacture medicines. 
    Patient access programs: participate in programs that provide 
free or subsidized medicines to targeted patient populations. 
    Pro-bono research: donate research staff time, resources, 
or facilities to organizations that are developing essential 
medicines.
    Public-private partnerships: create formal partnerships with 
the public sector and NGOs to successfully implement the 
recommended tools for corporate responsibility. 
    Research and development investments: increase investment 
in medicines and vaccines for diseases affecting predominantly 
poor people in the developing world (i.e., ‘neglected’ diseases).
    Stakeholder collaborations: engage with all stakeholders to 
ensure access-to-medicines initiatives address country priorities, 
are integrated into national structures, and avoid ‘vertical’ and 
‘parallel’ systems.
    Transfer of knowledge and collaboration on production 
in developing countries: create wholly-owned subsidiaries in-
country or provide licenses to local manufacturers. 
    Voluntary licensing: participate in patent pools or negotiate 
licensing agreements with entities that develop and manufacture 
medicines for patients in LMIC.
However, there is no consensus among pharmaceutical 
companies on which activities they “ought to” pursue or 
prioritize. Nor is there evidence about which activities are the 
most effective. Differential pricing seems to be a promising 
strategy [42,43] since it satisfies corporate responsibility goals 
by improving access to medicines for the poor and, theoretically, 
maximizes profits through price discrimination. However, the 
success of differential pricing depends on the ability to regulate 
arbitrage, accurately forecast the market for medicines, and 
distribute medicines through a functioning health system [43].
Several companies are applying differential pricing; it will be 
important to share successes and set-backs so that the industry 
can improve upon this strategy.
In addition to the “must,” “ought to,”and “can” activities, 
there are activities that industry “must not” engage in. An 
important example is inappropriate marketing. Industry must 
not use misleading, dishonest, or illegal promotional practices, 
such as promoting uses of medicines that will not benefit 
patients and misrepresenting results from the medical literature 
and clinical trials.
Given the human tragedy associated with inadequate access 
to medicines, strategies to improve access should be a 
corporate responsibility priority for the pharmaceutical industry. 
Pharmaceutical companies’ business models, and legitimacy, will 
increasingly depend on being perceived as a force for good in the 
fight against poverty-related illnesses and premature mortality. 
Corporate initiatives, however, cannot have their optimal impact 
if other stakeholders are not also doing their parts. The most 
sophisticated break-throughs in research and the most generous 
offers of low-priced medicines will make little difference for 
the poorest people if there is no basic health infrastructure to 
reach them [44]. Lack of health care infrastructure, insufficient 
workforce, logistic challenges, particularly in remote rural 
areas, and patient factors, such as misperceptions and stigma 
about disease and medicines, lack of health education, and 
poor adherence, necessitate extensive system investments. The 
pooling of resources, skills, experience, and goodwill across 
multiple stakeholders is necessary for sustainable solutions. 
Dialogue and collaborations are needed. 
Access to Medicines - A Call for Joint 
Action
Consistent with encouraging multi-stakeholder discussions 
at the Third International Conference for Improving Use of 
Medicines, [45] we recommend the creation of “solution-
stakeholder-teams” that include national governments, the 
international community, NGOs, pharmaceutical companies, 
and academics from multiple disciplines including medicine, 
public health, business, and ethics. Each team member brings 
unique perspectives and strengths to the development and 
implementation of collaborative strategies for sustainably 
improving access to medicines. Initial collaborations would 
focus on issues of common interest and win-win strategies. 
Examples include developing new antibiotics, increasing access 
to medicines for non-communicable diseases, and curbing sales 
of counterfeit and substandard medicines. While there are 
significant differences in opinion over the extent, depth, and 
breadth of pharmaceutical corporations’ actions to improve 
medicines access, there is basic agreement that differential 
pricing, donations, licenses, and pro bono research services are 
important elements.Formal evaluation of the impacts of joint 
interventions must be part of the solution-stakeholder-teams’ 
responsibilities [45].
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We believe that awarding “reputation capital” for companies 
that actively and collaboratively expand activities in the “ought 
to” and “can,” and curb activities in the “must not,” categories 
of corporate responsibility will eventually encourage more 
companies to engage in more activities to improve access to 
medicines for the poor. Indeed, a “must,” “ought to,” “can,” 
and “must not” approach may be valuable to define and assess 
fulfillment of responsibilities of each stakeholder in the complex 
pharmaceutical sector.     
We close with a notion of Jeffrey Sachs: “Modern businesses, 
especially the vast multinational companies, are the repositories 
of the most advanced technologies on the planet and the most 
sophisticated management methods for large-scale delivery 
of goods and services. There is no solution to the problems 
of poverty, population, and environment without the active 
engagement of the private sector [46].”
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